vaccines
vaccines

GSK Divests Two Travel Vaccines

GlaxoSmithKline plc (NYSE: GSK) announced recently it is selling two travel vaccines to Bavarian Nordic for $334.7 million upfront, plus a potential $1.06 billion in milestone payments. The sale included rabies vaccine Rabipur (tradename Rabavert in the United States) and Encepur, for the prevention of tick-borne encephalitis. GSK obtained the vaccines as part of a 2015 deal […]

Xiidra, Dry Eye Treatment Drug, Acquired by Novartis

The global pharmaceutical giant Novartis (NYSE: NVS) bought the assets to Xiidra 5% solution from Takeda Pharmaceutical Company (NYSE: TAK). The announcement gives us the largest pharmaceutical deal of the year so far, with Novartis paying $3.4 billion upfront and $1.9 billion in potential milestones for the drug. In 2018, Xiidra generated revenue of $400 million. Xiidra is the first and only […]